JP2020504184A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504184A5
JP2020504184A5 JP2019557668A JP2019557668A JP2020504184A5 JP 2020504184 A5 JP2020504184 A5 JP 2020504184A5 JP 2019557668 A JP2019557668 A JP 2019557668A JP 2019557668 A JP2019557668 A JP 2019557668A JP 2020504184 A5 JP2020504184 A5 JP 2020504184A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
isomer
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557668A
Other languages
English (en)
Japanese (ja)
Other versions
JP7150343B2 (ja
JP2020504184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/071964 external-priority patent/WO2018127207A1/zh
Publication of JP2020504184A publication Critical patent/JP2020504184A/ja
Publication of JP2020504184A5 publication Critical patent/JP2020504184A5/ja
Application granted granted Critical
Publication of JP7150343B2 publication Critical patent/JP7150343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557668A 2017-01-09 2018-01-09 チアゾール誘導体およびその使用 Active JP7150343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710014893 2017-01-09
CN201710014893.9 2017-01-09
PCT/CN2018/071964 WO2018127207A1 (zh) 2017-01-09 2018-01-09 噻唑衍生物及其应用

Publications (3)

Publication Number Publication Date
JP2020504184A JP2020504184A (ja) 2020-02-06
JP2020504184A5 true JP2020504184A5 (cg-RX-API-DMAC7.html) 2021-02-04
JP7150343B2 JP7150343B2 (ja) 2022-10-11

Family

ID=62789152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557668A Active JP7150343B2 (ja) 2017-01-09 2018-01-09 チアゾール誘導体およびその使用

Country Status (5)

Country Link
US (1) US10647710B2 (cg-RX-API-DMAC7.html)
EP (1) EP3566749A4 (cg-RX-API-DMAC7.html)
JP (1) JP7150343B2 (cg-RX-API-DMAC7.html)
CN (1) CN110225781B (cg-RX-API-DMAC7.html)
WO (1) WO2018127207A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3692039T2 (ro) 2017-10-05 2023-05-31 Innovative Molecules Gmbh Enantiomerii tiazolilor substituiți ca compuși antivirali
AU2019297214B2 (en) * 2018-07-06 2022-07-07 Phaeno Therapeutics Co., Ltd. Crystal forms of thiazole compound and application thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2025082442A1 (zh) * 2023-10-17 2025-04-24 辉诺生物医药科技(杭州)有限公司 (r)-5-卤素-2,3-二氢-1h-茚-2-羧酸的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
DE10210319A1 (de) * 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10226048A1 (de) * 2002-06-12 2003-12-24 Bayer Ag Thiazolylsulfonamide
RU2402553C2 (ru) * 2005-02-11 2010-10-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP6649284B2 (ja) * 2014-06-26 2020-02-19 ハイデルべルク イミュノセラピューティクス ゲーエムベーハー 抗hsv抗体の外用適用

Similar Documents

Publication Publication Date Title
PE20231438A1 (es) Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
CN115335372A (zh) 八氢吡嗪并二氮杂萘啶二酮类化生物
JP2020504184A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2014051526A5 (cg-RX-API-DMAC7.html)
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
JP2022081661A5 (cg-RX-API-DMAC7.html)
JP2006509749A5 (cg-RX-API-DMAC7.html)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2010536887A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2006524222A5 (cg-RX-API-DMAC7.html)
JP2018135343A5 (cg-RX-API-DMAC7.html)
CN113784970A (zh) Erk抑制剂及其应用
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
JP2014500861A5 (cg-RX-API-DMAC7.html)
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2014506907A5 (cg-RX-API-DMAC7.html)
JP2013544276A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2018502101A5 (cg-RX-API-DMAC7.html)
JP2012144537A5 (cg-RX-API-DMAC7.html)
CN111247151A (zh) 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用
JP2016510000A5 (ja) 治療用化合物